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The terminally differentiated podocyte, also called
glomerular visceral epithelial cell, are highly specialized
cells. They function as a critical size and charge barrier to
prevent proteinuria. Podocytes are injured in diabetic
and non-diabetic renal diseases. The clinical signature of
podocyte injury is proteinuria, with or without loss of renal
function owing to glomerulosclerosis. There is an exciting
and expanding literature showing that hereditary,
congenital, or acquired abnormalities in the molecular
anatomy of podocytes leads to proteinuria, and at times,
glomerulosclerosis. The change in podocyte shape, called
effacement, is not simply a passive process following injury,
but is owing to a complex interplay of proteins that comprise
the molecular anatomy of the different protein domains of
podocytes. These will be discussed in this review. Recent
studies have also highlighted that a reduction in podocyte
number directly causes proteinuria and glomerulosclerosis.
This is owing to several factors, including the relative inability
for these cells to proliferate, detachment, and apoptosis. The
mechanisms of these events are being elucidated, and are
discussed in this review. It is the hope that by delineating the
events following injury to podocytes, therapies might be
developed to reduce the burden of proteinuric renal diseases.
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Diabetic and non-diabetic glomerular diseases remain the
major cause of chronic and end-stage renal disease. What
makes the glomerulus fascinating, yet clinically challenging, is
that there are four resident cell types that are potentially
injured in different disease states. These include mesangial,
endothelial, visceral epithelial (also called podocytes), and
parietal epithelial cells. We and others classify glomerular
disease based on which resident glomerular cell type is injured,
as this provides a better understanding of why patients
present clinically with nephritic and/or nephrotic syndromes.
Diseases of mesangial cells (such as immunoglobulin (Ig)A
nephropathy, lupus nephritis) and endothelial cells (such as
thrombotic microangiopathy, lupus nephritis, mesangiopro-
liferative glomerulonephritis, and others) typically cause
nephritic syndrome. The parietal epithelial cell is a significant
component of crescents in most forms of crescentic glomeru-
lonephritis. In contrast, diseases of podocytes typically
present with proteinuria, with or without nephrotic
syndrome (Table 1). It should be noted that not all cases of
nephrotic range proteinuria are owing to podocyte diseases,
because the glomerular filtration barrier also comprises the
glomerular endothelial cell (GEN) and glomerular basement
membrane (GBM). Damage to these glomerular structures
may therefore also present with nephrotic-range proteinuria,
such as anti-GBM disease or thrombotic microangiopathy,
respectively.
The focus of this forum is on podocytes, specifically how
they respond to injury or damage, and how these events lead
proteinuria and glomerulosclerosis.
Normal podocyte structure
Gross structure. Podocytes are highly specialized, termin-
ally differentiated epithelial cells, with a quiescent pheno-
type.1 Podocytes derive embryonically from mesenchymal
cells.2 Each mature podocyte has distinct anatomical, and
therefore functional, components.3 The cell body is at the
center of the cell, and essentially lies in the urinary space.
Herein lies the cell’s nucleus, Golgi apparatus, and other cell
machinery such as endoplasmic reticulum and mitochondria.
From the cell body arise long primary processes, the ends
of which contains foot processes. Foot processes in turn
attach to the underlying GBM via integrins4 and dystro-
glycans,5 thereby anchoring this cell to the glomerular tuft.
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Foot processes from neighboring podocytes overlap (inter-
digitate). The ‘filtration slit’ formed between adjacent
interdigitating podocyte foot processes is a highly specialized
gap junction called the slit diaphragm, which forms the
major size barrier to protein leakage (see later for more
details in slit diaphragm proteins).
Molecular structure. Podocytes are polarized cells. Their
unique shape is owing to an abundantly rich actin cyto-
skeleton, which serves as the podocyte’s ‘backbone’.6 The
actin cytoskeleton also enables podocytes to continually and
dynamically alter shape, and also serves as a static function.
The cytoskeleton comprises three distinct ultrastructural
elements: (i) microfilaments (7–9 nm diameter), intermediate
filaments (10 nm), and microtubules (24 nm). Microfila-
ments are the predominant cytoskeletal constituents of the
foot process, and contain a dense network of F-actin and
myosin. As will be discussed later, there are several actin-
binding proteins such as synaptopodin7 and a-actinin-48
in podocytes, which are important in maintaining podocyte
shape.
The actin cytoskeleton is linked with other proteins.
Kerjaschki9 has classified podocytes into apical, basal, and
junctional cell membrane domains, based on the molecular
anatomy at each site. The junctional domain of proteins
comprises those proteins comprising slit diaphragm proteins.
Tryggvason was the first to discover nephrin,10 a member of
the Ig superfamily, as one of the now increasing number
of complex slit diaphragm proteins. The cytoplasmic tail
of nephrin binds to podocin.11–13 Nephrin also interacts
with and localizes to CD2AP.14,15 More recently, another Ig
superfamily of proteins have been identified called Neph-1,
which interacts with nephrin, podocin, and FAT1.16,17 Other
slit diaphragm proteins include ZO-1, Neph-2 and -3, and
densin.18 By forming the only connection between adjacent
podocytes, the slit diaphragm limits protein leakage by
acting as a size barrier, analogous to a sieve. One is also
left speculating that the slit may also function as a charge
barrier, as some of these proteins are phosphorylated. As will
be discussed later, certain slit diaphragm proteins actively
participate in podocyte signaling, thereby enabling the slit to
communicate with other podocyte proteins such as the actin
cytoskeleton.
The apical membrane domain of podocytes is negatively
charged, owing to the presence of the surface anionic proteins
podocalyxin,19 podoplanin,20 and podoendin. This serves
two functions. First, negative charge limits the passage of
albumin (also negatively charged). Second, adjacent podo-
cytes maintain separation by anion charge. The basal domain
is required to anchor podocyte to the underlying GBM. a3b1
integrin21 and a- and b-dystroglycans22 serve this function,
and connect the body of the podocyte to certain matrix
proteins within the GBM.
Table 1 | Diseases of the podocyte
Podocyte disease Cause of injury Mechanism/mediator
Membranous nephropathy Anti-podocyte antibodies C5b-9
Minimal change disease T cell mediated Not well defined
Classic FSGS Hereditary a-Actinin-4 mutation
Podocin mutation
CD2AP haploinsufficiency
Increased Pgc owing to: Podocyte stress–tension
K Obesity
K Diabetes
K Hypertension
K Reduced nephron number
kPodocyte number Apoptosis
Detachment
Lack of proliferation
DNA damage
Hypertrophy
Circulating factors Permeability factor(s)
Sporadic disease a-Actinin-4 mutation
Podocin mutation
Cellular/collapsing FSGS Infections HIV
Parvo B19?
Drugs Pamidronate
Interferon
Diabetic nephropathy Metabolic Hyperglycemia
Increased Pgc Podocyte stress–tension
Amyloid Amyloid protein deposition Amyloid spicules directly injure podocyte
MPGN Deposition of antigen–antibody complexes Splitting of GBM
Podocyte effacement
FSGS, focal segmental glomerulosclerosis; GBM, glomerular basement membrane.
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Podocyte function
The complex architecture of constitutive proteins is required
for the highly specialized functions of podocytes, which
includes (i) a size barrier to protein; (ii) charge barrier to
protein; (iii) maintenance of the capillary loop shape; (iv)
counteracting the intraglomerular pressure; (v) synthesis and
maintenance of the GBM; (vi) production and secretion of
vascular endothelial growth factor (VEGF) required for GEN
integrity. Therefore, it comes as little surprise that perturba-
tions in one or more of these functions following podocyte
injury underlies the signature clinical findings including
marked proteinuria, typically nephrotic range, and often a
decrease in renal function with elevated creatinine, both of
which will be discussed in detail below.
CAUSES OF PODOCYTE INJURY
From a clinical prospective, the predominant causes of
nephrotic range proteinuria in adults owing to podocyte
damage include focal segmental glomerulosclerosis (FSGS),
membranous nephropathy, minimal change disease, mem-
branoproliferative glomerulonephritis, amyloid, and diabetic
nephropathy. However, for the most part, these diseases are
named according to histologic descriptions of each disease,
and do not inform one of the causes and mechanisms of each
disease entity. The causes of podocyte injury in each disease
entity are shown in Table 1, and each will be described briefly.
The classification of podocyte injury preferred by the
author is to classify podocyte diseases into congenital,
hereditary, and acquired causes. The latter is further divided
into immune and non-immune causes. Congenital causes
include abnormalities in structural podocyte proteins, and
this is best exemplified by congenital nephrotic syndrome of
the Finnish type. In this disorder, there are several different
mutations in nephrin leading to a loss of normal podocyte
function, resulting in the onset of fetal proteinuria.23,24
Recent studies have shown that another congenital cause of
podocyte damage is the development of maternal antibodies
to neutral endopeptidase25 and metallomembrane endopep-
tidase26 in mothers who are deficient in the enzyme. As the
fetus has the neutral endopeptidase antigen and the mother
does not, the mother develops antibodies to this antigen,
which cross the materno–fetal circulation, and deposit in
podocytes, giving rise to membranous nephropathy. Ronco
and Debiec25 have recently shown a role for anti-neutral
endopeptidase antibodies in certain cases of childhood onset
membranous nephropathy. These antibodies are acquired
in utero, and thus can be considered congenital. One of
nephrin’s binding partners, CD2AP gives rise to proteinuria
in patients who have CD2AP haploinsufficiency.27
There are several hereditary causes of podocyte injury and
proteinuria, and these typically include mutations in
podocyte-specific proteins, of which mutations in a-acti-
nin-4 and podocin are best defined. Pollak and co-workers
identified that mutations in the podocyte actin-associated
protein, a-actinin-4, causes autosomal-dominant FSGS.8
Proteinuria typically develops in adulthood. Antignac
and co-workers were the first to report that mutations in
the slit diaphragm protein podocin causes autosomal-
recessive steroid-resistant nephrotic syndrome and FSGS in
children.28 More recently, mutations in TRPC6, a newly
discovered slit diaphragm protein, also leads to hereditary
proteinuria.29,30
The majority of podocyte diseases are acquired, and these
can be considered immune and non-immune mediated. The
characteristic immune-mediated forms of podocyte injury
are membranous nephropathy and minimal change disease,
although one might also consider membranoproliferative
glomerulonephritis associated with cryoglobulins as immune-
mediated podocyte injury. The antibodies that cause ‘idio-
pathic’ membranous nephropathy remain elusive in man.
Kerjaschki and Farquhar identified the Heymann nephritis
antigenic complex, now called megalin, in rats as the auto-
antigenic target.31 Minimal change disease is considered
immune-mediated because it is likely owing to an abnormality
in T cells, although the precise mechanisms are not well
defined.
Non-immune causes of acquired podocyte injury
are multiple. These include infectious causes such as
HIV-associated nephropathy giving rise to the characteristic
collapsing glomerulopathy owing to the local infection of
podocytes by the HIV virus.32 Many speculate that Parvo
B19 virus may also induce collapsing glomerulopathy in
HIV-negative patients. The prototypical metabolic cause
of podocyte injury is diabetes. Although diabetic nephro-
pathy has long been considered a mesangial disease, it is also
associated with significant podocyte injury (and hence
marked proteinuria).33 There is an increasing body of
literature showing that stress–tension, a result of increased
intraglomerular pressure, causes podocyte injury.34,35 This is
likely one of the final common pathways in systemic
hypertension, diabetic nephropathy, the metabolic syndrome,
and any cause of a reduced nephron number such as reflux
nephropathy, or chronic glomerulopathies. Infiltrative dis-
eases of podocytes are not common, and include amyloid,
where studies have shown that individual amyloid spicules
‘project’ through the GBM, penetrating into the overlying
podocytes. Finally, although the vast majority of slit
diaphragm protein mutations are congenital or hereditary,
recent studies have shown that sporadic FSGS can arise owing
to mutations in podocin.36 This leads one to ask if these
patients have a ‘two-hit’ injury, that is, a gene mutation that
by itself may not be sufficient to cause proteinuria, but in the
presence of a second injury, such as hypertension or
hypercholesterolemia, podocyte injury ensues.
HISTOLOGIC CHANGES IN PODOCYTES FOLLOWING INJURY
Although serological and other laboratory tests are informa-
tive in glomerular diseases, the definitive diagnosis in most
nephrotic syndromes is a renal biopsy. However, the range of
abnormalities seen on pathological examination of the renal
biopsy can be highly variable in diseases of podocytes. At one
extreme, despite massive proteinuria, light microscopy can be
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normal, such as minimal change disease. The other extreme is
exemplified by classic or cellular FSGS, where glomerulo-
sclerosis and glomerular tuft collapse are marked on light
microscopy, with or without changes in podocyte number
(increase or decrease).
Regardless of the cause of podocyte damage, typical
podocyte abnormalities are best seen on electron microscopy
and include vacuolization, microcystic, or pseudocystic
changes, the presence of cytoplasmic inclusion bodies,
and detachment from the GBM. In areas of reduced podo-
cyte number, there may be focal areas of denudation of
the underlying GBM. Although these changes are common,
the characteristic response to podocyte damage/injury is a
change in shape called effacement, and this will be
discussed in detail below. It should be noted that these
electron microscopy changes do not typically distinguish one
podocyte disease from another, but rather represent a
common final pathway of the podocyte’s response to injury.
HOW DOES PODOCYTE INJURY CAUSE PROTEINURIA AND
GLOMERULOSCLEROSIS?
The clinical signature of podocyte damage is proteinuria, and
in many instances, reduced renal function. The level of
proteinuria can range from mild (o3 g/day) to nephrotic
range (43 g/day). The author will now focus the discussion
on the mechanisms underlying proteinuria in response to
podocyte injury (see Figure 1, Tables 2 and 3).
PODOCYTE EFFACEMENT
What is podocyte foot process effacement?
In 1957, Farquhar et al.37 was the first to describe extensive
foot process effacement in biopsies of patients with nephritic
syndrome. Most authorities believe that effacement, also
often referred to as fusion, retraction, or simplification, is a
stereotypical reaction of podocytes to injury or damage.
Scanning electron microscopy has shown that the change in
podocyte shape called effacement consists of gradual
simplification of the inter-digitating foot process pattern,
resulting in the formation of a cell that looks flat and
elongated. This is not fusion of neighboring cells. Rather,
it is owing to retraction, widening, and shortening of the
processes of each podocyte. The frequency of filtration slits is
reduced,38 giving the appearance of a continuous cytoplasmic
sheet covering the GBM. Effacement is not specific to one
disease, but rather is synonymous with podocyte injury of
many forms.
Animal models showed that effacement starts as a decrease
in the degree of interdigitation by shortening and widening
of foot processes. This is accompanied by degradation of
some foot processes, followed by loss of the inter-digitating
foot process pattern between individual cells. Foot process
length decreases up to 70%, and the width increases up to
60% compared to normal. The resultant abnormal cell shape
comprising a flattened and spread out cell is what we know
as effacement. Studies have shown that effacement is not
simply a passive phenomenon, but rather is an active process
that is energy dependent, and is initiated by changes in the
podocyte’s cytoskeleton.
Podocyte effacement and proteinuria: What is the chicken
and what is the egg?
The author does not know the answer to this seemingly easy
question, and believes that there may be three views, and that
Podocyte injury owing to specific disease
Repair
Damage to glomerular
filtration barrier
Proteinuria and effacement
Resolution
Yes No
Proteinuria and glomerulosclerosis 
Figure 1 | Podocyte response to injury. Podocytes are injured by
immune- and non-immune-mediated disease, resulting in damage to
the glomerular filtration barrier. This typically results in proteinuria
and effacement. The fate of the podocyte then depends on several
factors, such as reparative mechanisms. If these are present, and/or
the initial injury is halted, there may be resolution. However, if injury
persists, and/or there are inadequate repair mechanisms presents,
proteinuria persists, with the development of glomerulosclerosis,
leading to reduced renal function.
Table 2 | Mechanisms leading to proteinuria following
podocyte injury
Cause of proteinuria following
podocyte injury Specific podocyte defect
Slit diaphragm proteins Nephrin mutation in man
Podocin mutation in man
CD2AP haploinsufficiency in man
FAT-1-targeted deletion in mice
Neph-1-targeted deletion in mice
Reduced podocyte number Detachment
Apoptosis
Lack of adequate proliferation
DNA damage
Hypertrophy
Podocyte effacement Changes in slit diaphragm proteins
Abnormal podocyte–GBM interaction
(a,b dystroglycans, a3b1 integrin)
Actin cytoskeleton reorganization
owing to synaptopodin, a-actinin-4,
CDK5
Loss of negative charge
Injury to apical membrane proteins
(podocalyxin, NHERF2, Ezrin)
Loss of podocyte anion charge kPodocalyxin
kGLEPP
Abnormal GBM Proteases from podocyte
Oxidants from podocyte
GBM thickening owing to matrix
accumulation from podocyte
kHeparan sulfate proteoglycan
Glomerular endothelial cell
dysfunction
kVEGF from podocyte
CDK, cyclin-dependent kinase; GBM, glomerular basement membrane; GLEPP,
glomerular epithelial protein; NHERF, Na+/H+-exchanger regulatory factor; VEGF,
vascular endothelial growth factor.
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the truth lies somewhere in between these. The first view is
that effacement itself is sufficient to cause proteinuria. There
are numerous examples where podocyte effacement is
accompanied by proteinuria in experimental models and
human disease. Indeed, one is usually hard pressed to find
marked proteinuria without effacement in human disease.
Data shows that indeed effacement precedes proteinuria in
experimental models such as puromycin aminonucleoside
nephrosis.39 Effacement results in a decrease in the filtration
slit frequency along the GBM and has been associated with
narrowing of the filtration slits and development of actual
tight junctions between foot processes.40 Effacement also
causes apical displacement of the slit diaphragm. These data,
while association only, lead one to speculate that once a
podocyte undergoes effacement from a specific cause, it is
sufficient to cause proteinuria.
The second view is that effacement is the final common
pathway to one of several abnormalities in, or injuries
to, podocytes, and therefore is not the cause of pro-
teinuria. Thus, in this scenario, effacement itself does not
cause proteinuria, but is rather a ‘marker’ for the actual
cause of proteinuria (see below for causes of effacement).
This view suggests that podocyte effacement is not
required for proteinuria, and that one can have significant
podocyte abnormalities in the absence of effacement.
Support for this notion comes from Chugh and co-
workers, who induced proteinuria by disrupting the Neph1–-
nephrin complex with specific antibodies, and showed
proteinuria with preserved foot processes.41 Salant’s group
also showed proteinuria in rats following the administration
of the anti-5-1-6 (nephrin) antibody, in the absence of
effacement.42
The third school of thought is that effacement can occur
independent of proteinuria, and that foot process effusion is
not a necessary consequence of proteinuria.43 For example, a
recent study by Lahdenkari44,45 showed that effacement can
occur in the absence of proteinuria. Van den Berg and co-
workers studied humans with minimal change nephrotic
syndrome and showed significant differences in the degree of
effacement in patients with minimal change nephrotic
syndrome, membranous nephropathy, and IgA, and that
the differences were independent of the level of proteinuria.46
Rather, the authors showed that it was the widths and shape
of the slit diaphragms that correlated with proteinuria. Foot
process width was 580 nm, whereas untreated minimal
change nephrotic syndrome patients had a mean foot process
width of 1600 nm. Further studies are clearly needed to verify
these interesting observations, and to provide increased
molecular understanding of these events.
Of interest is how effacement might explain the decrease
in glomerular filtration rate in certain nephrotic states. It is
estimated that the filtrations slits provide for 50% of the
hydraulic resistance of the glomerular capillary wall. Recall
that the ultrafiltration coefficient (Kf) is determined by the
total length of the filtration slit between foot processes. The
latter is decreased by foot process effacement. Thus, the
decrease in total slit length and number of slit diaphragms
owing to effacement may explain the decreased hydraulic
permeability of the filtration barrier as well as decreased
glomerular filtration rate in certain nephrotic diseases such as
minimal change disease.45
Actin cytoskeleton: the backbone of podocyte shape
As stated earlier, one of the major functions of podocytes
is to provide structural support to the glomerular tuft.
Foot processes are highly dynamic in large part owing to a
rich actin cytoskeleton.47,48 Microtubules and vimentin-type
intermediate filaments are distributed in the cell body and
primary processes. In the major processes, the cytoskeleton is
composed mainly of microtubules, interwoven with inter-
mediate filament proteins. Microtubule-associated protein-2,
-3, and -4, as well as Tau protein have been described in
podocytes. In contrast to the cytoskeletal proteins in the cell
body and major processes, foot processes have an elaborate
microfilamant-based contractile apparatus composed of
actin, myosin-II, a-actinin, talin, and vinculin. As will be
discussed below, these anchor to entire foot process to the
underlying GBM via integrins.
Table 3 | Mediators and effects following podocyte injury
Mediator from podocyte Effect
Reactive oxygen species Creation of holes in GBM
Podocyte apoptosis
Podocyte DNA damage
Effacement
Lipid peroxidation
Protein peroxidation
Angiotensin II Podocyte apoptosis
Podocyte hypertrophy
Increases TGF-b levels-matrix
accumulation
Increases VEGF levels-matrix
accumulation
Reduces nephrin levels
Increases p27 levels
Increases IP-8 and IP-10 levels
Metalloproteinases Alteration in GBM matrix
Disruption of nephrin–NEPH2 complex
Prostaglandins Endoplasmic reticulum stress
Mechanical stretch Podocyte detachment
Podocyte apoptosis
Inhibition of podocyte proliferation
Podocyte hypertrophy
TGF-b Increase in matrix proteins leading to GBM
thickening
Podocyte apoptosis
Increases metalloproteinases
SPARC Podocyte detachment
cAMP ?Narrowing of filtration slits
?Podocyte relaxation
VEGF mTGF-b levels
mProduction of a3(IV) collagen by
podocytes
Signaling pathways ERK, JNK, SAPK
ERK, extracellular signal-regulated kinase; GBM, glomerular basement membrane;
JNK, c-Jun NH2-terminal kinase; NEPH, nephrin-neutral endopeptidase; SAPK, signal-
activated protein kinase; SPARC, secreted protein acid rich in cysteine; TGF-b,
transforming growth factor-b; VEGF, vascular endothelial growth factor.
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The actin cytoskeleton ultimately determines the podo-
cyte’s shape. Proteins regulating or stabilizing the actin
cytoskeleton are therefore critical in the normal function of
the podocyte, and any alterations in the actin itself, or in
actin-regulating proteins, might lead to changes in podocyte
shape, and therefore function. Ichimura et al.48 demonstrated
that within adult podocytes, the actin cytoskeleton is divided
into two populations: (i) actin bundles that run along the
longitudinal axis of foot processes above the level of the slit
diaphragm, and (ii) a cortical actin network that distributes
beneath the plasma membrane of the foot process. Foot
process effacement is usually associated with an increase in
the microfilaments.
Dontscho Kerjaschki9 described three cell membrane
domains (apical, basal, and slit diaphragm) of podocytes in
his articulate review. Each of these domains, and the actin-
associated proteins, synaptopodin and a actinin-4, ultimately
connect to, and therefore have the potential to regulate, the
actin cytoskeleton. The effect of each membrane domain and
the actin-associated protein will now be discussed below in
the context of the development of effacement as a response to
podocyte injury.
CAUSES OF PODOCYTE EFFACEMENT
Actin-associated proteins
The major podocyte actin-binding proteins are a-actinin and
synaptopodin (Table 4).
Alpha actinin-4. a-Actinin-4 is an actin filament cross-
linking protein, and thus co-localizes with actin in podocytes.
Podocyte foot process effacement is preceded by an increase
in a-actinin-4 levels in experimental proteinuric disease.49
a-Actinin-4 mutations in man is associated with proteinuria
and effacement,8 and either knocking out or overexpressing
a-actinin-4 in mice leads to proteinuria and effacement.50,51
Synaptopodin
Synaptopodin is a novel class of actin-associated proteins,
without homology to any other class of proteins, and was
discovered by Peter Mundel.7 It is expressed in podocytes,
and in telencephalic dendrites. Synaptopodin is a proline-rich
linear protein and contains two high score PEST (a sequence
rich in proline (P), glutomic acid (E), serine (S) or threonine
(T)) sites, which target proteins for rapid degradation.
However, until a recent landmark paper by Mundel and
co-workers, its function has been an enigma.52 Mundel has
recently shown that there are three synaptopodin isoforms in
podocytes, named synaptopodin-long, -short and -T. Mundel
showed that in podocytes, synaptopodin interacts directly
with a-actinin-4. Moreover, synaptopodin modulates the
expression of a-actinin, by elongating a-actinin-induced
actin filaments.
The function of synaptopodin has been delineated
utilizing null mice.52 Administering protamine sulfate to
mice causes podocyte effacement. The recovery is normal in
wild-type mice given heparin, which neutralizes protamine
sulfate. In contrast, recovery from effacement is abnormal in
synpatopodin-null mice given protamine sulfate then hepar-
in. Taken together, synpatopodin has a critical role in
maintaining normal podocyte shape, and likely does this by
altering a-actinin-4 function.
Slit diaphragm proteins and podocyte effacement
The discovery of nephrin by Karl Trygvvason was an
incredible milestone in our understanding of what prevents
proteins from traversing the slit diaphragm. There are several
reviews that the reader is encouraged to read for a more in-
depth discussion on individual slit diaphragm proteins, as
these are beyond the scope of this discussion.
The inter-digitiating foot processes form a 40 nm wide
filtration slit. Two adjacent podocytes form a continous
membrane-like structure that we call the slit diaphragm,
which is the size barrier to proteins. Studies have shown that
nephrin, a transmembrane adhesion protein of the Ig
superfamily encoded by NPHS1 gene, is one of the major
proteins constituting the slit diaphragm reviewed by
Tryggvason.53 Mutations in the genes encoding proteins for
nephrin results in proteinuria. A second protein, podocin,
encoded by the gene called NPHS2, has been shown to bind
to nephrin. Podocin-null mice or patients with podocin
mutations develop proteinuria, and patients typically have
steroid-resistant nephrotic syndrome.11,28 The multi-adapter
protein CD2AP cloned by Shaw has been shown to also
interact with nephrin at the slit diaphragm.15 CD2AP-null
mice die of massive proteinuria, and CD2AP haploinsuffi-
ciency leads to glomerular disease in humans.27 Other slit
diaphragm proteins including Neph1 and FAT1 also complex
with nephrin, and targeted deletions in mice lead to
proteinuria.16,41,54,55 It is clear that the slit acts like a sieve,
in that it is the significant size barrier to protein.
Of note, in mice and man, mutations/abnormalities in the
slit diaphragm proteins listed above all display foot process
effacement. Administration of anti-Neph1 and anti-nephrin
result in rapid disorganization of the actin cytoskeleton,
leading to podocyte effacement.41,42 This raises the question
how might a slit diaphragm protein regulate podocyte shape,
Table 4 | Causes of podocyte effacement
Mechanism underlying effacement Mediator of effect
Changes in slit diaphragm proteins Nephrin
Podocin
FAT-1
CD2AP
Neph1
Abnormal podocyte–GBM interaction Integrins
Integrin-linked kinase
SPARC
Actin cytoskeleton reorganization Rho GTPases
a-Actinin-4
Synaptopodin
CDK5
Changes in negative charge Podocalyxin
GLEPP
CDK, cyclin-dependent kinase; SPARC, secreted protein acid rich in cysteine.
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which as discussed earlier, is ultimately owing to changes in
the actin cytoskeleton. Elegant studies by Benzing and Walz
have shown that slit diaphragm proteins are not static, but
rather are constantly involved in signaling processes.17 Thus,
slit diaphragm proteins send signals regulating the podocyte’s
polarity, survival, and cytoskeleton organization. Several
studies have elucidated how slit diaphragm proteins interact
with proteins ‘outside’ of the slit diaphragm to regulate
normal podocyte shape and therefore effacement following
injury. CD2AP connects the nephrin complex with the actin-
modifying proteins WASP, CAPZ, cortactin, and the Arp2/3
complex. The protein ZO-1 directly associates with the
cortical actin cytoskeleton, and Densin binds to a-actinin-
4.18 FAT-1 is also an organizer of actin polymerization. Taken
together, there is an increasing body of literature showing
that the actin cytoskeleton is regulated in part through
signaling pathways from specific slit diaphragm proteins.
Thus, when slit diaphragm proteins are injured/mutated,
in addition to loss of the size barrier, there is also loss of actin
arrangement (i.e. cytoskeleton disorganization), leading to
podocyte effacement and proteinuria. Salant’s group showed
the fraction of membrane-associated nephrin that is bound
to actin is diminished in experimental membranous nephro-
pathy, changes that correspond to alterations in podocyte
morphology.56 Taken together, several studies favor the
notion that proteinuria associated with effacement is not
owing to effacement per se, but is rather owing to increased
protein leak at the level of the slit diaphragm, and that
effacement is a consequence of slit diaphragm protein
damage.
Changes in podocyte–GBM interaction
The basal cell membrane domain of the podocyte has also
been shown to have a role in maintaining cell shape. Two
important constituents include the a3b1 integrin and a and b
dystroglycans, which serve as matrix receptors for podocytes,
and thus serve to tether podocytes to the GBM (reviewed by
Kretzler57).
a- and b-Dystroglycans are normally localized in a linear
pattern outlining the contours of the capillary loops in the
‘soles’ of podocytes.5 The a chain contains a polyanionic
binding site for the cationic laminin globular-binding
domain common to several matrix proteins such as laminin,
agrin, perlecan, and proteoglycans. The non-covalently
attached b chain links the dystroglycan complex to the
cortical actin cytoskeleton. The levels of dystroglycan are
reduced in minimal change disease, and are redistributed in a
clustered manner in FSGS, diseases associated with podocyte
effacement. Proof of principle was provided by Kerjaschki
and co-workers, who showed that injury to podocytes with
reactive oxygen species or protamine sulfate directly splits the
attachments of dystroglycans, and this leads to the induction
of podocyte effacement.58
Integrins are heterodimeric transmembrane molecules
mediating cell–matrix interactions. The major podocyte
integrin is a3b1, which binds collagen, fibronectin, laminin,
and entactin/nidogen in the GBM.59 Blocking b1 intergins
with an antibody induces foot process fusion and effacement,
as well as podocyte detachment. Kreidberg et al.21 used a
genetic approach, and showed that in the b1-null mouse,
podocytes are effaced. These mice die at birth. Integrin-linked
kinase is involved in cell signaling and Kretzler’s group60 has
shown that abnormalities in this lead to podocyte effacement
and proteinuria.
Cell cycle proteins and podocyte shape
We recently showed that a novel cell-cycle-protein, called
cyclin-dependent kinase 5 (CDK5), is constitutively
expressed in normal mature podocytes in vitro and in vivo.61
CDK5-null mice are embryonically lethal owing to neuro-
logical defects. In order to explore the role of CDK5, Griffin
et al.61 reduced CDK5 levels in cultured podocytes with either
small interfering RNA or a specific inhibitor, Roscovitine. In
both circumstances, reducing CDK5 levels or activity resulted
in a marked change in podocyte shape. Interestingly,
unlike other cyclin-dependent kinases, CDK5 has no role in
podocyte proliferation.
Changes in the apical membrane proteins
In addition to preventing proteinuria by acting as a size
barrier, podocytes, like the GBM on which it sits, also act
as a negative charge barrier to prevent the passage of
anionic proteins. This is owing to the constitutive presence
of the anionic apical proteins called podocalyxin and
podoplanin.
Podocalyxin is a heavily sialyated and sulfated membrane
protein belonging to the family of sialomucins. Neutraliza-
tion of the anionic surface charge with protamine sulfate or
by removal of sialic acid leads to foot process flattening, and
rearrangement of the cell junction between adjacent podo-
cytes.62 The levels of podocalyxin are virtually suppressed by
exposing cultured podocytes to high glucose conditions, and
podocalyxin levels were also reduced in the streptozotocin rat
model of experimental diabetic nephropathy.63 Podocalyxin
overexpression inhibits cell–cell adhesion, and likely serves
to maintain an open filtration pathway between neighboring
foot processes, and neutralizing the charge affects cell–cell
adhesion and junctional permeability. These studies have
recently been extended by Farquhar, who showed recently
that the cytoplasmic domain of podocalyxin is linked to the
actin cytoskeleton through Naþ /Hþ -exchanger regulatory
factor (NHERF)/ezrin complexes,64 and that podocalyxin is
required to maintain foot process structure in vivo. Taken
together, podocalyxin functions to maintain podocyte shape
by linking to the actin cytoskeleton, and a decrease in levels
or loss of anionic charge leads to podocyte shape changes
(effacement) and distortion of the slit diaphragm, both
leading to proteinuria.
Podoplanin is a 43 kDa glycoprotein.65 Levels are reduced
in the puromycin aminonucleoside nephrosis model. Studies
have shown that injecting rats with an anti-podoplanin
antibody results in podocyte effacement, and proteinuria.
Kidney International (2006) 69, 2131–2147 2137
SJ Shankland: Podocyte injury r e v i e w
CHANGES IN PODOCYTE NUMBER: THE LINK TO
GLOMERULOSCLEROSIS
Evidence and relevance for reduced podocyte number in
disease
There is an increasing body of experimental and clinical
literature showing a decrease in podocyte number in diabetic
and non-diabetic glomerular disease (Table 5).66–69 Wiggins
showed that aging is also associated with reduced podocyte
number. The consequences of reduced podocyte number
include proteinuria and glomerulosclerosis. The mechanism
underlying proteinuria is simply owing to a lack of charge
and size selectivity in areas of podocyte loss, as these barriers
are now devoid. Studies have shown that proteinuria
increases as podocyte number decreases.33,67,68
Recent studies have also correlated podocyte loss with the
onset and magnitude of glomerulosclerosis. The reader is
referred to excellent reviews by Kriz for the explanation how
reduced podocyte number leads to glomerulosclerosis, as this
is beyond the scope of the current discussion.66,70,71 In brief,
podocyte loss leads to areas of ‘bare or denuded’ GBM where
podocytes are reduced. Because one of the functions of
podocytes is to maintain capillary loop shape by opposing
the outward forces of glomerular pressures (which are
increased in many renal diseases), podocyte loss leads
to outward bulging of the GBM in the denuded areas. A
synchial attachment forms upon contact of the denuded
GBM with the parietal epithelial cells and Bowmans capsule.
This is the first ‘committed step’ for the formation of FSGS.
Podocyte number reflects the balance between processes
that favor an increase in cell number, and those that favor a
decrease in cell number. In most, but not all forms of
progressive glomerular disease, the factors favoring a decrease
in podocyte number prevail, and hence overall number
decreases. We see this clinically as proteinuria and increasing
creatinine. The causes of reduced podocyte number are
discussed below (Figure 2).
Podocyte detachment: hanging on needing to stay attached
Podocytes are normally tethered to the underlying GBM by
integrins and dystroglycans, and are essentially ‘floating’ in
the urinary space. It has been known for some time that
podocytes and certain podocyte-specific protein products can
be detected in the urine from patients with proteinuric renal
disease, but are typically absent in healthy subjects, and in
non-podocyte glomerular diseases.72–77 More recent studies
have shown the presence of intact podocytes in the urine in
experimental and clinical studies of diabetic and non-diabetic
glomerular diseases. Interestingly, Lemley and Petermann78–81
showed that many of the podocytes present in the urine in
disease are indeed viable. Pichler recently showed that high
glucose levels itself is sufficient to cause detachment of
cultured podocytes (personal communication). Yu et al.81
have recently shown that perhaps the presence of podocytes
in the urine is a more sensitive marker than proteinuria.
Taken together, these studies show that podocytes are present
in the urine in certain diseased states.
The mechanisms of podocyte detachment have not been
well delineated. Recall that podocytes attach to the GBM
by adhering to underlying matrix GBM proteins via intergins
and dystroglycans. Thus, an obvious hypothesis is that altera-
tions in the levels or activities of these ‘adherence molecules’
favors detachment of podocytes from the GBM. Indeed,
studies have shown a decrease in a3b1 integrin in diabetes,82
and it is therefore tempting to speculate that this might
underlie podocyte detachment in diabetic nephropathy.
Finally, as will be discussed below, once podocytes
detach from the GBM, they are also extremely vulnerable
to undergoing apoptosis.
Podocyte apoptosis: a life or death decision
A second cause underlying a decrease in podocyte number is
increased programmed cell death, also called apoptosis. There
is an emerging experimental and clinical literature showing
that apoptosis is a major cause of reduced podocyte number,
leading to proteinuria and/or glomerulosclerosis. Bottinger
was among the first to show increased podocyte apoptosis in
experiments performed in tumor growth factor-b (TGF-b)
transgenic mice.83 Wiggins and co-workers showed podocyte
apoptosis in the puromycin aminonucleoside nephrosis
model of podocyte injury, and that glomerulosclerosis was
only first detected following a 20% reduction in podocyte
number.84 Moreover, there was a direct correlation thereafter
between reduced podocyte number and increased sclerosis.
What are the causes of podocyte apoptosis? A simple view
is that the decision whether a cell undergoes apoptosis or
Table 5 | Podocyte number in glomerular diseases
Podocyte number
normal
Podocyte number
decreased
Podocyte number
increased
Membranous
nephropathy
Membranous
nephropathy
HIV-associated
nephropathy
Minimal change
disease
Diabetic nephropathy Cellular/collapsing
FSGS
Classic FSGS Classic FSGS Crescentic
glomerulonephrtitis
Amyloid
Aging
FSGS, focal segmental glomerulosclerosis.
Podo
number
•Detachment
•Apoptosis
Prolif
eratio
n
Loss
•Lack of DNA
synthesis
•DNA Damage
•Hypertrophy
Figure 2 | Factors governning podocyte number. Total podocyte
(podo) number is a balance between proliferation and loss. Podocyte
number is reduced by either a decrease in proliferation owing to lack
of DNA synthesis, DNA damage or hypertrophy, and/or an in crease in
podocyte loss owing to detachment and apoptosis.
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survival and injury is that this fate is ultimately the balance
between pro- and antiapoptotic (i.e. survival) factors. These
are discussed below (Table 6).
Survival mechanisms in podocytes. What prevents podo-
cytes from dying, and what keeps podocytes alive following
injury? One obvious response to this question is that proteins
or molecules that are constitutively present in a cell are
essential for normal function, such as survival. This raises
several candidates. Accordingly, recent studies have focused
on the possibility that specific slit diaphragm proteins govern
podocyte survival. Clues emerged from CD2AP-null mice,
where Schiffer et al.89 showed that podocyte apoptosis was
increased significantly in these mice compared to CD2AP
–wild-type mice. A role for CD2AP in protecting podocytes
from death was further validated when the proapoptotic
cytokine TGF-b increased apoptosis in cultured podocytes
derived from CD2AP-null mice compared to control.
These authors, and Benzing’s group86 showed that CD2AP
selectively engages the phosphatidylinositol 30-kinase kinase/
AKT antiapoptotic signaling pathway. When CD2AP is absent
or likely reduced, active (phosphorylated) AKT is dramati-
cally reduced, and this is associated with increased suscept-
ibility to podocyte apoptosis.
Recent data from Benzing has also shown a role for
nephrin in reducing podocyte apoptosis.86 Nephrin too
increases Akt activity, and thereby reduces podocyte
apoptosis. Saleem showed that podocytes mutant for nephrin
have increased apoptosis in response to serum starvation
compared to wild-type cells.98 This effect was related to
nephrin phosphorylation. Saleem showed that VEGF reduces
apoptosis in podocytes expressing nephrin, but that this
survival effect was absent in nephrin mutant cells. The
mechanism for this effect is that VEGF-induces phosphor-
ylation of nephrin. Taken together, nephrin is required for
podocyte survival, and by phosphorylating nephrin, VEGF
secreted by podocytes acts as an autocrine survival factor, as
perhaps does insulin-like growth factor-1.95 Griffin from our
group recently showed that cyclin I, which is constitutively
expressed in normal podocytes, functions as a survival factor.
Podocyte attachment is a critical survival mechanism. As
stated earlier, once podocytes detach from the GBM, their
susceptibility and propensity to undergo apoptosis increase
significantly. However, the mechanisms for this remain
unclear. Thus, although no published studies have yet shown
a direct role, one can speculate that a3b1 integrin and the
dystroglycan complex are required for podocyte survival by
facilitating adhesion to the GBM. What happens to
podocytes if the constituents of the GBM upon which
podocytes sit are altered. Cybulsky’s group showed that
cultured podocytes grown on collagen have increased
survival, an effect that was mediated through the activation
of focal adhesion kinase and the Ras–ERK signaling path-
way.93 These studies give rise to the notion that perhaps in
diseases where the matrix proteins of the GBM are altered
following podocyte injury, such as membranous and diabetic
nephropathy, podocyte survival is reduced. Finally, Wada
et al.91 from our group has shown a role for Bcl-2 in
protecting podocytes from apoptosis.
More recently, Wada showed that dexamethasone mark-
edly reduces podocyte apoptosis in cultured podocytes in
response to puromycin aminonucleoside and TGF-b.91 This
novel non-immunological effect is owing to a decrease in p53
levels by dexamethasone. More studies are needed to fully
understand the mechanisms involved in the protective
actions of dexamethasone on podocyte apoptosis.
Proapoptotic factors in podocytes. The cytokine TGF-b
and its receptors increase in a variety of podocyte diseases,
including membranous nephropathy, diabetic nephropathy,
and FSGS. In addition to its profibrotic effects, there is now
an emerging literature showing that TGF-b also induces
podocyte apoptosis. Schiffer et al.83 have delineated some
of the downstream mediators of TGF-b-induced podocyte
apoptosis. They showed that SMAD-7 augments TGF-b-
induced apoptosis, and that p38 mitogen-activated protein
kinase and caspase-3 are required for TGF-b to induce
podocyte apoptosis.
Our group has focused on delineating the nuclear events
in TGF-b-induced podocyte apoptosis, and focused on
the CDK inhibitor p21. The rationale for this is that like
TGF-b, p21 is increased in podocytes in experimental
membranous nephropathy (PHN model),99 diabetic nephro-
pathy (Streptozotocin model),100 and minimal change disease
(PAN model). Wada et al.88 showed that TGF-b increases
p21 levels in cultured podocytes. To determine if p21 was
required for the apoptotic effects of TGF-b, p21-null
podocytes in cultured were studied. The results showed that
TGF-b only induced apoptosis in wild-type podocytes where
p21 was present (and increased by TGF-b), but not in
p21-null podocytes. However, reconstituting p21 expression
in p21-null podocytes by transfection restored the apoptotic
response to TGF-b. Taken together, in addition to certain
signaling events, the CDK inhibitor p21 is necessary for
TGF-b-induced apoptosis.
Table 6 | Regulation of podocyte life and death
Proapoptotic Antiapoptotic (prosurvival)
Angiotensin II34,85 Cyclin I
AT1 receptor
34,85 Nephrin86,87
TGF-b 83,88 CD2AP89,86
Cyclosporine90 Dexamethasone91
SMAD 783 Bcl-291
Reactive oxygen species Cell–cell contact
Detachment VEGF87
kp2192 Collagen via Ras-ERK signaling93
kp2794 Focal adhesion kinase93
Hyperglycemia Insulin-like growth factor-195
Stress–tension96 Hepatocyte growth factor90
bFGF97
Lytic concentrations of C5b-9
p5391
Apoptotic-inducing factor91
bFGF, basic fibroblast growth factor; ERK, extracellular signal-regulated kinase; TGF-b,
transforming growth factor-b; VEGF, vascular endothelial growth factor.
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There is a large clinical literature showing that inhibiting
angiotensin II and/or its receptor with a angiotensin-
converting enzyme inhibitor and angiotensin receptor
blocker, respectively, improves proteinuria, and that this
benefit is independent of blood pressure lowering. These
studies suggested that angiotensin II has deleterious effects
directly on the kidney, independent of its hemodynamic
actions. Indeed, Singhall showed that angiotensin II directly
causes podocyte apoptosis, an effect that is mediated through
the AT1 receptor.85 Durvasula et al.34 showed that when
cultured podocytes are placed under stress–tension (induced
by mechanical stretch), they apoptose. However, blocking the
AT1 receptor pharmacologically significantly reduced stres-
s–tension-induced podocyte apoptosis. Taken together, in
addition to reducing systemic and intraglomerular pressures,
angiotensin II blockade likely also reduces podocyte apop-
tosis, thereby minimizing podocyte loss, providing an
additional mechanism explaining how these agents reduce
proteinuria and glomerulosclerosis.
It has been well established that diabetes is associated with
reduced podocyte number, and that this correlates with the
onset and magnitude of proteinuria.33 We and others29,30
have shown that hyperglycemia directly induces apoptosis in
cultured podocytes, thereby providing an additional possible
explanation to reduced podocyte number in this disease.
Puromycin aminonucleoside is a podocyte toxin, and
induces apoptosis.101 The mechanisms of this effect are being
clarified. We recently showed that this effect was mediated by
the tumor suppressor gene product, p53, because inhibiting
p53 prevented apoptosis.91 In addition, puromycin amino-
nucleoside also increases the levels of the proapoptotic
protein, Bax. Thus, the pathways underlying podocyte
apoptosis are becoming clearer.
Finally, many cells are more vulnerable to apoptosis
upon cell cycle entry. Our data show that podocyte apop-
tosis is increased in rats with the PHN model of mem-
branous nephropathy following administration of basic
fibroblast growth factor, coinciding with increased cell cycle
entry.99 Moreover, apoptosis is also increased when
podocytes proliferate in the absence of the CDK inhibitors
p2192 and p27.94
The studies discussed above show that there are now
several well-established pro- and antiapoptotic mechanisms
at play in podocytes, and that following injury, the balance of
these effects determines the cell’s fate to live or die. The latter
seems to predominate in instances of progressive glomerulo-
sclerosis, and suggests that future interventions should be
aimed at preventing or reducing podocyte apoptosis.
Lack of adequate podocyte proliferation
A third cause underlying reduced podocyte number is the
apparent lack of proliferation in response to injury.102
Podocytes are terminally differentiated epithelial cells, and
as such, seem to attempt to maintain this quiescent
phenotype at all costs, even at the expense of developing
glomerulosclerosis. Why then do podocytes not proliferate in
certain diseases such as membranous nephropathy, minimal
change disease, diabetic nephropathy, and classic FSGS, yet
proliferate in others such as collapsing/cellular FSGS and
crescentic glomerulonephritis? To answer this fundamental
question, we have focused our efforts on the role of specific
cell cycle regulatory proteins. The rationale for this approach
is that a cell’s growth phenotype is closely governed by its
state of differentiation, and that both these events may share
common regulatory control at the level of the cell cycle.
Studies have shown that the state of differentiation and
proliferation are indeed very closely linked in podocytes.
During glomerulogenesis, presumptive and immature un-
differentiated podocytes have a proliferative phenotype.2 In
contrast, mature adult podocytes have a quiescent phenotype.
Quiescent cells are in the G0 phase of the cell cycle (i.e. have
excited cell cycle). In order for differentiated cells such as
podocytes to proliferate requires that they de-differentiate
and then re-enter cell cycle at G1 phase. This is followed
by DNA synthesis in the S phase, and mitosis occurs in the
M phase. Cell division (called cytokinesis), which follows
mitosis, is strictly speaking not part of the cell cycle.
Based on the relationship between podocyte differentia-
tion and proliferation, we consider diseases of podocytes as
those that remain differentiated and quiescent (minimal
change disease classic FSGS, membranous nephropathy,
diabetes), and those that de-differentiate and proliferate
(cellular/collapsing FSGS, crescentic glomerulonephritis). I
will now discuss what governs the decision of these cell fates
at the level of the cell cycle. In order for a cell to transition
through the cell cycle, specific cyclins must bind to and
activate partner CDKs at each phase of the cell cycle.103,104
However, certain CDK inhibitors limit proliferation by
inhibiting target cyclin–CDK complexes.
Cyclins and CDK’s in podocytes. Cyclin D1 increases
following podocyte injury, as does the protein levels of cyclin
A and its partner CDK2 in the passive Heymann nephritis
model of membranous nephropathy.99,105 Thus, podocytes
undergo DNA synthesis, albeit at very low levels. This is in
stark contrast from mesangial cells, where cyclin A–CDK2
activity is markedly increased in mesangial proliferative
glomerulonephritis.106 These data show that the lack of
podocyte proliferation in the majority of podocyte diseases is
not owing to the lack of the cell cycle machinery (i.e. cyclins
and CDKs) required to proliferate. More recently, studies
have shown that podocytes do proliferate in crescentic
glomerulonephritis.107 Our data show that CDK2 activity is
markedly increased in experimental crescentic glomerulone-
phritis.108 Inhibiting CDK2 activity with Roscovitine
significantly reduces podocyte proliferation in this model,
and improves renal function. CDK2 inhibition also
significantly improves renal function in experimental HIV-
associated nephropathy109 and experimental membranous
nephropathy.110
Why then does CDK2 activity and hence DNA synthesis
increase in some (collapsing/cellular FSGS and crescentic
glomerulonephritis), but not other (classic FSGS, membra-
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nous, and diabetes) podocyte diseases. One possibility is that
the catalytic partners for CDKs are not increased. There is
little support for this because cyclins D1, A, and B increase in
podocytes following injury.111 The more likely explanation is
that despite an increase in cyclin–CDK levels, there is a
marked increase in CDK inhibitors, which reduce/inhibit
cyclin–CDK activity, and this will now be discussed.
CDK inhibitors in podocytes. Although there are two
families of CDK-inhibitors, little is known about the role
of the inhibitors of CDK4 (INK) family (p15, 16, 18, 19)
in podocytes. The discussion will therefore focus on the role
of the CDK-interacting protein/kinase inhibitor protein
(CIP/KIP) family of CDK inhibitors (p21, p27, p57). In the
normal human and rodent glomerulus, staining for p21 is
absent, but there is a constitutive expression of p27 and
p57.112 Within the glomerulus, p57 staining is restricted
to podocytes.112
p21. There is a marked increase in p21 levels in podo-
cytes in experimental membranous nephropathy (PHN
model), coinciding with the lack of proliferation.99 Moreover,
p21 was shown to bind to and inhibit cyclin A–CDK2 in this
model. To test the role for p21 in governing podocyte
proliferation, we induced injury in p21-wild-type and p21-
null mice. Podocyte proliferation was markedly increased in
nephritic p21-null mice compared to nephritic p21–wild-type
mice, and this was associated with worse renal function.92
These results are consistent with the notion that p21 limits
podocyte proliferation following injury.
p27. In cultured immortalized podocytes, the switch
from a proliferative and undifferentiated phenotype to a
non-proliferative and quiescent phenotype coincides with
an increase in p27 protein levels.113 In the PHN model
of membranous nephropathy, p27 levels increase in
podocytes.99 By extracting protein from isolated glomeruli,
we showed that p27 also has increased affinity for cyclin
A–CDK2 complexes. To test the role of p27 in governing
podocyte proliferation, experimental injury was induced in
wild-type and null mice.94The onset and magnitude of
glomerular proliferation was markedly increased in nephritic
p27 null, and the majority of the cells proliferating were
podocytes. This was associated with increased accumulation
of matrix proteins, and a decline in renal function compared
to nephritic wild-type mice. In human disease, p27 levels
do not decrease in non-proliferative podocyte diseases
such as classic FSGS, minimal change, and membranous.112
In contrast, p27 levels decrease in collapsing FSGS, and this
corresponds to the increase in podocyte proliferation in this
disease. Taken together, p27 is a critical regulator of podocyte
proliferation following injury.
p57. We are particularly interested in p57 because
expression is limited to podocytes under normal condi-
tions.113 p57 levels do increase coinciding with immortalized
podocytes become quiescent in culture.113 p57 levels decrease
in proliferating podocytes in vivo in experimental glomerular
disease. Like p27, p57 levels decrease in areas of podocyte
proliferation in human collapsing FSGS, whereas p57 levels
remain unchanged in non-proliferative human podocyte
disease.112p57-null mice are embryonically lethal, making the
study of these mice currently invalid to test the precise role of
this CDK inhibitor. Taken together, the author speculates that
p57 may not be required to maintain podocyte quiescence
under normal conditions, but is required to limit prolifera-
tion following injury.
Podocyte proliferation
The conventional thought has been that podocytes do not
proliferate. However, using genetically manipulated mice that
express green-colored podocytes, Holzman and co-workers
showed that podocytes proliferate and increase in number
in experimental crescentic glomerulonephritis.107 Recent
studies also support the notion that podocytes proliferate
in collapsing/cellular FSGS, although this has been more
difficult to prove.114 In experimental HIV-associated nephro-
pathy, Klotman’s group showed that the NEF antigen of
the virus is sufficient to induce podocyte proliferation.115
This is owing to a decrease in the CDK inhibitor p27, and
an increase in cyclins D1 and Nelson et al.109 showed that
reducing podocyte proliferation with a CDK2 inhibitor
improved overall renal survival and reduced proteinuria.
Taken together, a change in podocyte number, whether
a decrease (as occurs in most glomerular diseases) or an
increase, is detrimental to normal glomerular function. The
mechanisms underlying reduced and increased podocyte
number will be discussed in further detail.
DNA damage
Although we have reported that one mechanism underlying
the apparent lack of adequate proliferation was an abnorm-
ality in DNA synthesis, we have also recently shown that
another possibility is an abnormality in mitosis owing to a
block at the G2/M checkpoint of the cell cycle. When
quiescent cultured mesangial cells and podocytes are exposed
to antibody and a complement source to induce sublytic
injury (defined as less than 5% lactate dehydrogenase
release), both cell types enter the cell cycle at G1 phase.
116,117
In mesangial cells, this is followed by robust DNA synthesis,
and completion of the cell cycle, with resultant proliferation
and increased cell number.118 In contrast, podocytes undergo
DNA synthesis, albeit limited, but do not proliferate because
they arrest at the G2/M phase of cell cycle.
117 In seeking to
determine the mechanisms underlying this difference, we
showed that sublytic C5b-9 injury causes DNA damage in
podocytes, but not in mesangial cells.119 DNA damage
prevents proliferation by arresting cells at G2/M phase. In
podocytes, DNA damage was accompanied by an increase in
p53, p21, GADD45, and checkpoint kinase-1 and -2.119These
proteins coordinate to halt the cell cycle at the G2/M
checkpoint, thereby arresting cells before mitosis. More
recently, Marshall from our group showed that DNA damage
also occurs in podocytes in response to other forms of
injuries, such as puromycin aminonucleoside, and that this is
mediated in part by reactive oxygen species. As shown in
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Table 3 oxidants therefore reduce podocyte number by at
least two mechanisms, apoptosis and DNA damage.
Hypertrophy
An interesting response to podocyte injury is an increase
in cell size owing to hypertrophy.120–122 This is defined
biochemically as an increase in the cell’s protein to DNA
ratio, accompanied by increased cell volume. This requires
that the cell enters the cell cycle in G1, which leads to protein
synthesis, and thus an increase in protein content. However,
cells arrest at the G1/S checkpoint, thereby preventing an
increase in DNA content, which would have occurred at S
phase. These events lead to an increased cellular protein:DNA
ratio, and increased cell size (but not number). There are
several studies that have shown podocyte hypertrophy in vivo,
including in diabetic nephropathy and FSGS.
Why do podocyte’s hypertrophy? The belief is that
podocyte hypertrophy is initially adaptive, and that this is
an attempt by a cell that is relatively incapable of proli-
ferating, to cover the underlying GBM and thus reduce
proteinuria in denuded areas where neighboring cells have
detached or apoptosed. However, with time, it is likely that
podocyte hypertrophy becomes maladaptive. Cell culture
studies have shown potential mechanisms underlying this
observation. First, high glucose is sufficient to cause podocyte
hypertrophy in vitro.123 This might be mediated by an
increase in angiotensin II, which itself, can cause hypertro-
phy. Angiotensin II-mediated podocyte hypertrophy might
be regulated through an increase in the CDK inhibitor p27,
which is increased in podocytes in vitro and in vivo in
diabetes. Nagata and co-workers showed that podocyte
hypertrophy may be owing to increased expression of specific
CDK inhibitors, p21 and p27.124
More recently, Petermann et al.125 from our group
showed that injuring cultured podocytes with mechanical
stretch inhibited proliferation, and switched the cell to a
hypertrophic phenotype. This was mediated by the CDK
inhibitor p21.
These studies show that despite entry into cell cycle, under
certain circumstance, podocyte’s arrest at the G1/S check-
point, and undergo a hypertrophic growth response. These
events therefore limit the podocyte’s ability to proliferate,
leading to a reduction in overall podocyte number.
PODOCYTE INJURY LEADS TO ABNORMALITIES IN THE GBM
Matrix accumulation
Studies have shown that the GBM serves as a charge, and
perhaps size barrier to proteins. It is therefore of little
surprise that injury to the GBM, such as occurs in anti-GBM
disease and Alport’s syndrome, may result in proteinuria. As
discussed earlier, podocytes are closely adherent to the GBM,
begging the question that following podocyte injury, is the
GBM impacted in any way. Several excellent reviews describe
the normal matrix protein makeup of the GBM, which is
beyond the scope of this discussion.126 Recall that the GBM
itself is acellular, and thus cannot make its own matrix
proteins. In states where the GBM is thickened, such as
membranous and diabetic nephropathies, this is owing to an
increase in the accumulation of ‘new’ and usually ‘abnormal’
matrix proteins, which are produced by the overlying injured
podocytes. One can therefore speculate that the change in
composition of the GBM in these states of podocyte injury
disturb the normal GBM architecture, and thus function,
leading to proteinuria directly, or as described earlier,
indirectly by inducing podocyte apoptosis.
Oxidants
In several types of podocyte injury in vitro127 and in
experimental diseases such as membranous nephropathy
(PHN model), diabetic nephropathy, minimal change disease
(PAN model),128 and other models,129 injured or damaged
podocytes increase the production and release of oxidants.130
Oxidants in turn cause damage directly to podocytes,
including the induction of apoptosis, DNA damage, and
likely lipid and protein oxidative stress (Table 3).131,132
However, oxidants also damage the underlying GBM, by
creating holes directly in the GBM. The latter leads to a
reduction in size barrier, and results in proteinuria. Oxidants
likely also induce proteinuria by other mechanisms.
Oxidants induce foot process effacement, and administering
antioxidants to rats with PAN normalizes podocyte shape,
and reduces proteinuria in this model, and in experi-
mental membranous nephropathy.130 Finally, oxidants
also disrupt a3-integrins in experimental proteinuric renal
disease, leading to proteinuria.133
Proteinases
During glomerulogenesis, podocytes are required for the
synthesis of several extracellular matrix proteins that
constitute the GBM. Many believe that podocytes are also
required for the ‘maintenance’ of the GBM in the mature
glomerulus. The quantity of matrix proteins in any cell or
membrane is a balance between synthesis and degradation.
Metalloproteinases are proteinases specific for basement mem-
brane proteins, and serve to reduce the abundance of these
proteins such as type IV collagen, fibronectin, and laminin.
Cathepsin L, metalloproteinase-2, and metalloproteinase-9
are proteinases endogenous to podocytes, the activities of
which are increased by cytokines such as TGF-b.134
Metalloproteinase-9 is markedly increased in podocytes
following C5b-9 injury in experimental membranous
nephropathy.135 More recently, proteinases have been shown
to induce proteinuria by also interfering with nephrin-
neutral endopeptidase H interaction in the slit diaphragm.136
These studies show that the increase and release of
oxidants and proteinases by podocytes following injury may
alter the matrix constituents of the underlying GBM,
rendering it more leaky to protein. The author proposes
that a vicious podocyte–GBM–podocyte cycle then develops,
where the altered matrix proteins in the GBM now may lead
to deleterious effects on podocytes, such as apoptosis and
detachment.
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PODOCYTE INJURY LEADS TO ENDOTHELIAL CELL
DYSFUNCTION
The third component of the glomerular filtration barrier
is the GEN, which is a highly specialized fenestrated
cell. There is an interesting ‘cross-talk’ between podo-
cytes and GENs that is served by VEGF. GEN themselves
do not make VEGF, but have VEGF receptors. Earlier studies
showed that VEGF expression is reduced in diabetic
nephropathy, but the consequences of this were speculated
upon. Elegant genetics studies by Quaggin has care-
fully elucidated precisely how podocyte-secreted VEGF
regulates GEN development and function.137 Utilizing a
nephrin-cre-LoxP mouse model system to delete selectively
podocyte VEGF-A, Quaggin showed that loss of one
VEGF-A allele causes glomerular endotheliosis. Deleting
both VEGF-A alleles prevents the formation of the glomer-
ular filtration barrier. Interestingly, overexpressing VEGF-A
causes collapsing glomerulopathy. Taken together, a para-
digm is emerging whereby a decrease in podocyte secreted
VEGF leads to abnormal GEN function, which in turn
may lead to proteinuria. The role of VEGF as a podocyte
survival factor was discussed earlier. Thus, another mechan-
ism whereby podocyte injury leads to proteinuria is by
affecting GEN.
NEW THOUGHTS ABOUT OLD PODOCYTE THERAPIES, AND
NEW POSSIBILITIES ON THE HORIZON
I will end my discussion with a few thoughts on how old
therapies alter podocyte biology and thus proteinuria, and
briefly discuss potential new therapies.
Angiotensin blockade
One of the mainstays of treating proteinuria is angiotensin II
blockade. However, given that the proteinuric-reducing
effects are independent of blood pressure lowering suggests
that angiotensin II likely has local effects on podocytes
directly (Figure 3). Indeed, angiotensin II is increased in
podocytes following exposure to mechanical stretch and
hyperglycemia. Angiotensin II causes podocyte apoptosis,34,85
actin rearrangement, increased VEGF synthesis,138 increased
TGF-b levels,138 reduction of ZO-1 and nephrin levels leading
to proteinuria,139 and alterations in calcium and cAMP
signaling. Overexpressing the AT1 receptor in podocytes
causes marked glomerulosclerosis.140 Thus, inhibiting angio-
tensin II production or its receptor with an angiotensin-
converting enzyme inhibitor or angiotensin receptor blocker,
respectively, mitigates many deleterious effects on podocytes,
thereby reducing the response to injury.
Corticosteroids
Corticosteroids are the mainstay of therapy for several
proteinuric diseases. In addition to its immune-modulating
effects, recent studies have shown that corticosteroids may
have direct effects on podocytes. Wada et al.91 from our
group recently showed that dexamethasone reduced podocyte
apoptosis induced by puromycin aminonucleoside and
TGF-b. Dexamethasone prevented the increase in the
proapoptotic tumor suppressor gene, p53. Wada also showed
that dexamethasone altered the subcellular localization
of apoptotic inducing factor. Taken together, these studies
show that corticosteroids may reduce proteinuria and/
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Figure 3 | Injurious effects of angiotensin II on podocytes. The numerous deleterious actions of angiotensin II (AT) and its receptor are
shown, providing the rationale for the use of angiotensin-converting enzyme Inhibitors and angiotensin receptor blockers in patients with
proteinuria.
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glomerulosclerosis by preventing a decrease in podocyte
number. Ransom et al.141 recently showed that dexametha-
sone increases ciliary neurotrophic factor, aB-crystallin and
heat shock 27 in podocytes, which are viewed as kidney
protective proteins. The same group also showed that
dexamethasone enhanced actin stability against subsequent
disruption by cytochalsin D and latrunculin A. Thus,
corticosteroids may directly improve proteinuria and
effacement through a variety of factors, and also reduce
glomerulosclerosis by reducing podocyte apoptosis.
All-trans-retinoic acid
Podocytes express receptors for all-trans-retinoic acid
(ATRA). Several recent studies have shown a role for ATRA
in diabetic and non-diabetic proteinuric diseases).142 For
example, Vaughan from our group showed that giving ATRA
to rats with experimental podocyte disease significantly
improved proteinuria, and that this was likely owing to the
prevention of decreasing nephrin and podocin expression.143
We also have shown that ATRA reduces glomerulosclerosis in
HIV transgenic mice (M Fleet, unpublished data). The
protective effects of ATRA on podocytes need to be further
delineated.
CDK2 inhibitors
Several small molecule inhibitors have been developed in
the past decade, which target specific proteins, such as CDK2.
We recently administered the CDK2 inhibitor Roscovitine to
mice with experimental anti-GBM disease characterized by
podocyte proliferation.108 Our data showed that Roscovitine
improved proteinuria and blood urea nitrogen compared to
animals receiving vehicle. This was associated with a decrease
in podocyte proliferation. Nelson et al.109 recently showed
marked improvement in renal function in HIV transgenic
mice given the CDK2 inhibitor cyclacel, and Floege’s
group showed improvement in renal function when cyclacel
was given to rats with experimental membranous nephro-
pathy (PHN model).110 Taken together, there may be future
potential for the use of small molecule inhibitors in
proteinuric states owing to podocyte disease.
CONCLUSIONS AND FUTURE DIRECTION
In many glomerular diseases, the exact mechanisms causing
the disease are not yet fully delineated. However, our
understanding of the response to podocyte injury has
increased significantly in the past decade following the
explosion of molecular and cellular research in podocyte
biology. The response of podocytes to injury is complex, and
involves numerous processes. Many of these overlap in
several podocyte diseases, yet some are specific. The author
believes that we are in an exciting era where newer diagnostic
approaches, treatment guidelines, and prognostic indicators
based on molecular endpoints are on the horizon. It is the
hope that newer and specific therapies will also be developed
that alter the deleterious responses to podocyte injury,
thereby reducing the burden of renal disease. With the
exciting ongoing research efforts worldwide, there is hope for
our patients.
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